Literature DB >> 3591091

Antibiotic therapy in early erythema migrans disease and related disorders.

K Weber, U Neubert, R Thurmayr.   

Abstract

Between December 1978 and July 1985, we used various antibiotics for the treatment of 97 adult patients with early erythema migrans disease (EMD). Six patients with borrelial lymphocytoma (BL) and 20 with acrodermatitis chronica atrophicans (ACA) were treated similarly. Follow-up was for a median of 20, 14, and 12 months, respectively. The erythema migrans and all associated symptoms resolved within a median of 3 weeks (0.5-18.4), BL within 7 weeks (4-16), and ACA partly or completely within several months. A Jarisch-Herxheimer (-like) reaction was observed in 8 patients with EMD. Fourteen patients with EMD and one with ACA developed an exacerbation of symptoms or new manifestations between the 2nd and 20th day, and 28 patients with EMD and one with ACA continued to have or acquired various symptoms greater than or equal to 3 weeks after initiation of therapy. Arthralgia, neurologic and constitutional symptoms, and in one instance a slight pulmonary interstitial edema developed in EMD. More severe initial illness was a risk factor for the development of later symptoms in EMD. Retreatment was more often necessary in ACA than in EMD. A patient with ACA had a recurrence after 5 1/2 years. IgG antibody titers rose at least fourfold in 5 patients with ACA and in 1 with EMD despite therapy. We tentatively recommend minocycline or high doses of parenteral penicillin for the treatment of these disorders.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3591091     DOI: 10.1016/s0176-6724(87)80096-2

Source DB:  PubMed          Journal:  Zentralbl Bakteriol Mikrobiol Hyg A        ISSN: 0176-6724


  17 in total

1.  [Multiple erythema].

Authors:  B Brunner; U Neubert; M J Flaig; C A Sander
Journal:  Hautarzt       Date:  2003-03-25       Impact factor: 0.751

2.  Persistence of Borrelia burgdorferi and histopathological alterations in experimentally infected animals. A comparison with histopathological findings in human Lyme disease.

Authors:  V Preac Mursic; E Patsouris; B Wilske; S Reinhardt; B Gross; P Mehraein
Journal:  Infection       Date:  1990 Nov-Dec       Impact factor: 3.553

3.  In vitro susceptibility of thirty Borrelia strains from various sources against eight antimicrobial chemotherapeutics.

Authors:  R Baradaran-Dilmaghani; G Stanek
Journal:  Infection       Date:  1996 Jan-Feb       Impact factor: 3.553

Review 4.  Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease.

Authors:  Daniel J Cameron; Lorraine B Johnson; Elizabeth L Maloney
Journal:  Expert Rev Anti Infect Ther       Date:  2014-07-30       Impact factor: 5.091

5.  Effects of penicillin, ceftriaxone, and doxycycline on morphology of Borrelia burgdorferi.

Authors:  A Kersten; C Poitschek; S Rauch; E Aberer
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

6.  Treatment of borrelial lymphocytoma.

Authors:  F Strle; V Maraspin; D Pleterski-Rigler; S Lotric-Furlan; E Ruzić-Sabljić; T Jurca; J Cimperman
Journal:  Infection       Date:  1996 Jan-Feb       Impact factor: 3.553

Review 7.  Treatment failure in erythema migrans--a review.

Authors:  K Weber
Journal:  Infection       Date:  1996 Jan-Feb       Impact factor: 3.553

8.  Erythema migrans: three weeks treatment for prevention of late Lyme borreliosis.

Authors:  F Breier; G Kunz; H Klade; G Stanek; E Aberer
Journal:  Infection       Date:  1996 Jan-Feb       Impact factor: 3.553

9.  Polymerase chain reaction control of antibiotic treatment in dermatoborreliosis.

Authors:  R Muellegger; N Zoechling; E M Schluepen; H P Soyer; S Hoedl; M Volkenandt
Journal:  Infection       Date:  1996 Jan-Feb       Impact factor: 3.553

10.  Clarithromycin in treatment of early Lyme disease: a pilot study.

Authors:  R J Dattwyler; E Grunwaldt; B J Luft
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.